AGM
GYRE icon

Alpine Global Management’s Gyre Therapeutics GYRE Stock Holding History

Alpine Global Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-26
Closed -$93K – 165
2014
Q2 		$93K Buy
+26
New +$84.8K 0.03% 159

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Alpine Global Management's GYRE Position: Q3 2014 in Review

Alpine Global Management sold out of Gyre Therapeutics (GYRE) in Q3 2014, closing a stake of 26 shares — an estimated $93K sold.

Alpine Global Management first reported a position in GYRE in Q2 2014 and held it in 1 quarter. The position peaked at $93K in Q2 2014. 55 funds tracked by Wall St. Rank hold GYRE as of Q3 2014.

  • Alpine Global Management reported no remaining Gyre Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Alpine Global Management sold 26 Gyre Therapeutics shares in Q3 2014, an estimated $93K.
  • Alpine Global Management first reported a position in Gyre Therapeutics in Q2 2014 and held it in 1 quarter.
  • Alpine Global Management's Gyre Therapeutics position peaked at $93K in Q2 2014.
  • 55 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2014.

Based on Alpine Global Management's 13F filing for Q3 2014, filed 14 Nov 2014.